CONTACT US   |  (864) 397-5101

Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products


Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year

Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in early 2023

“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals,” commented Robert Hayes, Sharps Technology CEO. “The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”

The agreement also allows for Sharps Technology to utilize Nephron’s sales and marketing teams to further support the sale of the Company’s innovative products to targeted customers within the Nephron customer network. Nephron’s customer network includes a reach of more than 3,000 customers through a combination of direct and online sales through their web-based electronic portal system. This hybrid sales environment will allow for targeted marketing plans for the different types of customers within the network. Sharps will support the sales strategy with customer product in-servicing to facilitate specialized customer opportunities, which include the development of custom drug delivery solutions and private labeled product configuration needs.

The collaboration between Sharps and Nephron is expected to continue to grow as previously announced, as the companies move forward with the startup of the Inject-EZ operation in South Carolina in early 2023. We believe that this opportunity to support Nephron and co-manufacture a portfolio of specialized copolymer prefilled syringe systems will further advance the revenue plan for Sharps in late 2023 for these products. This partnership to co-produce these needed products for the pharmaceutical industry will pull forward Sharps’ plan to offer these products by more than two years.

Mr. Hayes concluded, “The distribution agreement will further accelerate the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The opportunity to pull forward our sales plan for customers here in the US will create a unique opportunity for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023. Sharps will be adding additional products to the distribution network by mid-year 2023 from its plant in Hungary as part of a phased manufacturing ramp-up strategy for the Company.”

About Sharps Technology, Inc.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary, and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. For additional information, please visit

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.